Next 10 |
home / stock / hjliw / hjliw news
Patient Shows Significant Improvement at One Year IRVINE, CA / ACCESSWIRE / December 1, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that the tenth VenoValve patient in HJLI's fi...
Patient Continues to Show Significant Improvement at One Year IRVINE, CA / ACCESSWIRE / October 21, 2020 / Hancock Jaffe Laboratories, Inc. (Nasdaq:HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that the ninth VenoValve patient ...
Companies Sign Non-Binding Letter of Intent to Merge IRVINE, CA / ACCESSWIRE / June 1, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the Company has signed a non-binding letter of in...
CoreoGraft Study Approved by the Superintendent of Health of the National Health Council of Paraguay IRVINE, CA / ACCESSWIRE / May 12, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that ...
VenoValve Patients Continue to Show Significant Improvement at One Year IRVINE, CA / ACCESSWIRE / April 28, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that five VenoV...
IRVINE, CA / ACCESSWIRE / April 27, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today it has entered into a securities purchase agreement with certain accredited institutional invest...
Presentation from Abstract to be Delivered at the Southern Association of Vascular Surgery Conference January 8 to 11 in Palm Beach, Florida IRVINE, CA / ACCESSWIRE / December 20, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices th...
Initial Implantation Phase for First-in-Man Study Now Completed IRVINE, CA / ACCESSWIRE / November 15, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that it has enrolled an...
VenoValve Patients Continue to Improve at 6 Months IRVINE, CA / ACCESSWIRE / October 24, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that Dr. Jorge Hernando Ulloa, the Pr...
IRVINE, CA / ACCESSWIRE / October 22, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that on Friday October 25, 2019, Dr. Jorge Hernando Ulloa, the Principal Investigator for HJLI's...
News, Short Squeeze, Breakout and More Instantly...
Hancock Jaffe Laboratories Inc. Warrants Company Name:
HJLIW Stock Symbol:
NASDAQ Market:
Patient Shows Significant Improvement at One Year IRVINE, CA / ACCESSWIRE / December 1, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that the tenth VenoValve patient in HJLI's fi...
Patient Continues to Show Significant Improvement at One Year IRVINE, CA / ACCESSWIRE / October 21, 2020 / Hancock Jaffe Laboratories, Inc. (Nasdaq:HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that the ninth VenoValve patient ...
Companies Sign Non-Binding Letter of Intent to Merge IRVINE, CA / ACCESSWIRE / June 1, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the Company has signed a non-binding letter of in...